CFIA Conceals Adverse Event Reports for Merck's New RNA Rabies Vaccines
The Canadian Food Inspection Agency (CFIA) is withholding adverse event reports tied to Merck Animal Health's newly approved RNA-particle rabies vaccines for pets. Documents obtained through Canada's Access to Information Act reveal that 29 cats, 65 dogs, and at least one human experienced adverse reactions connected to the Nobivac NXT Feline-3 Rabies and related products (vaccines that received Canadian authorization in June 2024). Every detail describing those adverse events has been fully redacted.
What the CFIA Is Hiding and Why It Matters
The CFIA cited two exemptions under the Access to Information Act: Section 19(1) (personal privacy) and Section 20(1)(c) (potential financial prejudice to third parties, meaning Merck). A formal complaint has since been filed with the Office of the Information Commissioner of Canada.
What we don't know (and what the CFIA is actively preventing us from knowing) includes the severity of the reactions, whether any were fatal, the nature of each adverse event (anaphylaxis, neurological symptoms, injection-site reactions), whether any animals died as a result, and whether the human adverse event involved a veterinary worker or a pet owner.
This level of opacity carries particular weight here because of what these vaccines are: a novel RNA-particle platform, recently commercialized, with a limited post-market track record, now being quietly introduced to family pets across North America.
What Makes the Nobivac NXT Platform Different From Traditional Rabies Vaccines
Before going further, it is worth being precise about the technology involved. Merck's Nobivac NXT series does not use lipid nanoparticle (LNP) delivery, and it is not identical to the COVID-19 mRNA vaccines made by Pfizer or Moderna. What it uses is called an alphavirus replicon RNA particle (ARRP) platform, specifically, genetic machinery derived from Venezuelan equine encephalitis virus (VEEV). No adjuvants are included.
Here is how it works in plain terms:
- A strand of self-amplifying RNA (saRNA) is packaged inside a protein shell that mimics a viral particle.
- That particle enters the animal's cells and delivers the RNA payload.
- The RNA uses built-in replicase machinery (borrowed from the VEEV alphavirus) to replicate itself inside the host cell.
- The replicating RNA instructs the cell to produce large quantities of the rabies virus surface protein (the antigen).
- The immune system mounts a response to that antigen.
Merck markets the self-amplifying feature as an advantage: it requires a lower initial RNA dose while theoretically generating a more robust immune response. A Merck-sponsored study published in November 2025 claimed 100% efficacy from a single dose in both cats and dogs, lasting over three years in animals as young as 12 weeks.
However, that same study noted:
- 3 out of 45 cats and 2 out of 42 dogs were removed from the trial for unspecified "health reasons unrelated to the vaccine" (a designation that raises obvious questions about how "unrelated" was determined and by whom).
- In field safety trials, 5.7% of cats and 6.8% of dogs experienced adverse events deemed related to vaccination.
- The study did not separately report adverse events classified as unrelated, and did not track potential fatalities.
To date, no peer-reviewed study from any party outside Merck has examined tissue distribution, multi-dose cumulative effects, or long-term safety outcomes of the Nobivac NXT platform in dogs or cats.
Four Reasons Regulatory Opacity Is Especially Concerning Here
1. This Is a Novel Platform With No Long-Term Track Record
Traditional killed-virus or recombinant rabies vaccines (Imrab, PUREVAX, Defensor) have decades of real-world use behind them. Their adverse event profiles, while imperfect, are reasonably well-characterized. Nobivac NXT does not have that history. Every withheld adverse event report is data the veterinary community needs to accurately assess this platform's risk profile. Hiding that data doesn't just fail transparency obligations; it actively impedes evidence-based veterinary practice.
2. Injection-Site Sarcomas Are Already a Known Risk in This Category
Merck's own published study acknowledged that adjuvanted vaccines have been linked to feline injection-site sarcomas (FISS), a deadly and aggressive cancer that can develop at repeated injection sites in cats. While Nobivac NXT does not use adjuvants (presented as a safety advantage), the study's own acknowledgment of this risk underscores that vaccine-associated cancers in cats are a live, documented concern in this space. Without knowing the nature of the redacted adverse events, injection-site pathology cannot be ruled out.
3. Veterinary Vaccines Are Not Liability-Indemnified in the United States
Unlike human vaccines in the United States (which are shielded from liability under the National Childhood Vaccine Injury Act), veterinary vaccine manufacturers can be sued. This makes adverse event transparency not only an ethical obligation but a practical one, and it makes the "financial harm" redaction rationale all the more conspicuous. If the product is as safe as claimed, what financial harm would disclosure of adverse event descriptions actually cause?
4. The Regulatory Culture Precedent Is Concerning
The Nobivac NXT line was approved on an accelerated regulatory pathway that paralleled the expedited mechanisms applied to COVID-19 mRNA vaccines in humans. One of the COVID bivalent boosters was authorized by the FDA in September 2022 after being tested on 8 mice, with no human trial data required beforehand. That same regulatory culture (speed over longitudinal safety data) is now being applied to products injected into companion animals. That culture produced significant post-market surprises in the human sphere; there is no structural reason to expect veterinary medicine to be different.
A Scientific Footnote Worth Knowing
Rabies virus, like coronaviruses, relies on RNA-dependent RNA polymerase (RdRp) for replication, the enzyme that copies the viral genome inside host cells. Early in vitro research has explored whether zinc ionophores such as chloroquine (and related compounds like quercetin, which acts as a natural zinc transporter) might inhibit rabies infection by interfering with RdRp activity, similar to mechanisms theorized for COVID-19. No significant follow-up studies have been published, and this is not a treatment recommendation. It is, however, a thread worth watching for those interested in the overlap between human and veterinary immune support research.
For those exploring herbal and nutritional approaches to supporting their pet's immune system more broadly, our holistic pet care resources page includes a curated library of books, video channels, and practitioner guides covering integrative approaches.
What Pet Owners Can Actually Do About This
Ask What You Are Being Given Before Every Appointment
Before any vaccine is administered to your pet, ask: "Does this vaccine use mRNA, RNA particle, or self-amplifying RNA technology?" Then ask to see the product label or package insert. On Merck labels, look for the phrases "RNA particle technology," "self-amplifying," or "alphavirus replicon." Any of these indicate a saRNA product.
If your vet is planning to administer a rabies vaccine in the U.S., traditional alternatives are still widely available:
| Traditional Alternative | Type | Notes |
|---|---|---|
| Imrab 1, 3, or 3TF | Killed virus | Widely available; adjuvanted |
| PUREVAX Rabies (cats) | Recombinant, non-adjuvanted | Popular with integrative vets; preferred for cats |
| Defensor | Killed virus | Standard companion animal rabies vaccine |
| NOBIVAC 1-Rabies | Killed virus | Merck's own traditional platform (still available) |
You can simply say: "I would prefer to use a traditional inactivated or recombinant vaccine rather than an RNA-platform product at this time. Can you confirm which product you are planning to administer?"
Ask Whether Your Pet Actually Needs a Booster Right Now
Many pets carry protective immunity well beyond the 1-3 year revaccination schedules printed on vaccine labels. Titer testing is a blood test that measures whether your pet still has circulating antibodies to a given disease. For non-rabies core vaccines (distemper, parvovirus, adenovirus, panleukopenia), a protective titer is recognized by the WSAVA and AAHA as a valid basis for deferring or skipping revaccination.
For rabies specifically, titers cannot legally substitute for vaccination in any U.S. state. However, they can support a medical exemption application in the approximately 17 states that allow one (particularly for animals with prior adverse vaccine reactions, immunocompromising conditions, or serious chronic illness).
Our full titer testing guide covers how the tests work, which labs to use, what to say to your vet, a state-by-state legal breakdown, how to identify RNA-platform vaccines, and how to pursue a medical exemption if your pet qualifies.
Know How to Report an Adverse Event
An adverse event does not have to be dramatic to be worth reporting. Symptoms emerging within days to weeks of vaccination (lethargy, swelling at the injection site, vomiting, neurological changes, behavior shifts, or loss of appetite) can and should be reported. Document the date of vaccination, the lot number printed on the syringe label, the product name, and a timeline of symptoms.
- United States: USDA APHIS Center for Veterinary Biologics at aphis.usda.gov/veterinary-biologics
- Canada: Canadian Food Inspection Agency adverse event reporting portal
- Your veterinarian (ask them to file the report officially in addition to your own submission)
This data matters. For a product as new as Nobivac NXT, post-market adverse event reporting is among the only mechanisms available for building an accurate real-world safety picture.
Find a Veterinarian Who Will Have This Conversation With You
Not every conventional veterinarian is familiar with titer testing, vaccine exemptions, or the specifics of RNA-platform products. If yours is not open to discussing alternatives, the American Holistic Veterinary Medical Association (AHVMA) maintains a practitioner directory at ahvma.org. Holistic and integrative vets typically have far more familiarity with individualized vaccination protocols and the nuances of risk-benefit assessment for sensitive animals.
The Bigger Picture
Merck's Nobivac NXT rabies vaccines are currently approved in Canada and rolling out in the U.S. through 2025 and 2026. Once widely stocked at veterinary clinics, the default will be to administer whatever is on the shelf, unless pet owners ask questions first.
The CFIA's decision to redact 95 adverse event reports does not tell us those events were severe. It tells us we are not allowed to know whether they were. That is a different kind of problem, and it belongs to every pet owner who has ever trusted a regulatory body to serve as their first line of defense.
Informed consent for your animals (as for your own body) has always required doing some of that work yourself. That is what these resources are here to support.
This article is for informational and educational purposes only. It does not constitute veterinary or legal advice. For individualized guidance, work with a licensed veterinarian, ideally one with holistic or integrative training.
